In addition to inhibition of platelet aggregation, GPIIb-IIIa antagonists may reduce thrombotic events via other mechanisms. In a novel whole blood flow cytometric system, we investigated the effects of GPIIb-IIIa antagonists, in the presence or absence of thrombin inhibitors, on platelet surface-bound factor V/Va and platelet surface phospholipids. Diluted venous blood was incubated with either buffer or a GPIIb-IIIa antagonist (abciximab, tirofiban, or eptifibatide). Some samples were pre-incubated with clinically relevant concentrations of unfractionated heparin (UFH), a low molecular weight heparin, a direct thrombin inhibitor, or buffer only. Platelets were then activated and labeled with mAb V237 (factor V/Va-specific) or annexin V (binds phosphatidylserine), fixed, and analyzed by flow cytometry. In the absence of thrombin inhibitors, GPIIb-IIIa antagonists (especially abciximab) significantly reduced agonist-induced platelet procoagulant activity, as determined by reduced binding of V237 and annexin V. At high pharmacologic concentrations, unfractionated heparin and enoxaparin, but not hirudin, further reduced factor V/Va binding to the surface of activated platelets in the presence of GPIIb-IIIa antagonists. Agonist-induced platelet procoagulant activity was reduced in a patient with Glanzmann’s thrombasthenia. We conclude that GPIIb-IIIa antagonists reduce platelet procoagulant activity in whole blood and heparin and enoxaparin augment this reduction. Fibrinogen binding to GPIIb-IIIa is important in the generation of platelet procoagulant activity.
1
Fuster V,
Badimon L,
Badimon JJ,
Chesebro JH.
The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
2
The Antiplatelet Trialist Collaboration.
Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 1540.
3
The PURSUIT Trial Investigators.
Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339: 436-43.
4
The PRISM STUDY Investigators.
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338: 1498-505.
5
The PRISM-PLUS Study Investigators.
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators [published erratum appears in N Engl J Med 1998 Aug 6; 339 (6): 415]. N Engl J Med 1998; 338: 1488-97.
6
The EPIC Investigators.
Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk angioplasty. N Engl J Med 1994; 330: 956-61.
7
The EPILOG Investigators.
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
8
The CAPTURE Study Investigators.
Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study [published erratum appears in Lancet 1997 Sep 6; 350 (9079): 744]. Lancet 1997; 349: 1429-35.
9
The EPISTENT Investigators.
Randomised placebo-controlled and balloonangioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.
10
Dachary-Prigent J,
Freyssinet JM,
Pasquet JM,
Carron JC,
Nurden AT.
Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood 1993; 81: 2554-65.
11
Sandberg H,
Andersson LO,
Hoglund S.
Isolation and characterization of lipid-protein particles containing platelet factor III released from human platelets. Biochem J 1982; 203: 303-11.
12
Rosing J,
van Rijn JL,
Bevers EM,
van Dieijen G,
Comfurius P,
Zwaal RF.
The role of activated human platelets in prothrombin and factor X activation. Blood 1985; 65: 319-32.
13
Sims PJ,
Wiedmer T,
Esmon CT,
Weiss HJ,
Shattil SJ.
Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-57.
19
Ammar T,
Scudder LE,
Coller BS.
In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997; 95: 614-7.
20
Moliterno DJ,
Califf RM,
Aguirre FV.
et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol 1995; 75: 559-62.
21
Dangas G,
Badimon JJ,
Coller BS.
et al. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol 1998; 18: 1342-9.
22
Pedicord DL,
Thomas BE,
Mousa SA,
Dicker IB.
Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res 1998; 90: 247-58.
24
Cheresh DA,
Spiro RC.
Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem 1987; 262: 17703-11.
25
Cheresh DA.
Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA 1987; 84: 6471-5.
26
Coller BS,
Peerschke EI,
Scudder LE,
Sullivan CA.
A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
28
Gralnick HR,
Williams SB,
McKeown L.
et al. Endogenous platelet fibrinogen: its modulation after surface expression is related to sizeselective access to and conformational changes in the bound fibrinogen. Br J Haematol 1992; 80: 347-57.
29
Michelson AD.
Flow cytometric analysis of platelet surface glycoproteins: Phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia. J Lab Clin Med 1987; 110: 346-54.
30
Michelson AD,
Ellis PA,
Barnard MR,
Matic GB,
Viles AF,
Kestin AS.
Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, ADP or an in vivo wound. Blood 1991; 77: 770-9.
31
Thiagarajan P,
Tait JF.
Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990; 265: 17420-3.
33
Raynal P,
Pollard HB.
Annexins: the problem of assessing the biological role for a gene family of multifunctional calciumand phospholipid-binding proteins. Biochim Biophys Acta 1994; 1197: 63-93.
34
Tam SH,
Sassoli PM,
Jordan RE,
Nakada MT.
Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and αvβ3 integrins. Circulation 1998; 98: 1085-91.
38
Santos MT,
Valles J,
Marcus AJ.
et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest 1991; 87: 571.
39
LaRosa CA,
Rohrer MJ,
Benoit SE,
Rodino LJ,
Barnard MR,
Michelson AD.
Human neutrophil cathepsin G is a potent platelet activator. J Vasc Surg 1994; 19: 306-18.
41
Nesheim ME,
Furmaniak-Kazmierczak E,
Henin C,
Cote G.
On the existence of platelet receptors for factor V(a) and factor VIII(a). Thromb Haemost 1993; 70: 80-6.
42
Alberio L,
Safa O,
Clemetson KJ,
Esmon CT,
Dale GL.
Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin (In Process Citation). Blood 2000; 95: 1694-702.
43
Hayward CP,
Furmaniak-Kazmierczak E,
Cieutat AM.
et al. Factor V is complexed with multimerin in resting platelet lysates and colocalizes with multimerin in platelet alpha-granules. J Biol Chem 1995; 270: 19217-24.
44
Coller BS,
Cheresh DA,
Asch E,
Seligsohn U.
Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann’s thrombasthenia in Israel. Blood 1991; 77: 75-83.
46
Gallo R,
Padurean A,
Toschi V.
et al. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation 1998; 97: 581-8.
48
Topol EJ,
Ferguson JJ,
Weisman HF.
et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997; 278: 479-84.
51
Fox JE,
Reynolds CC,
Austin CD.
The role of calpain in stimulus-response coupling: evidence that calpain mediates agonist-induced expression of procoagulant activity in platelets. Blood 1990; 76: 2510-9.
52
Fox JE,
Austin CD,
Reynolds CC,
Steffen PK.
Evidence that agonistinduced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J Biol Chem 1991; 266: 13289-95.
54
Defilippi P,
Venturino M,
Gulino D.
et al. Dissection of pathways implicated in integrin-mediated actin cytoskeleton assembly. J Biol Chem 1997; 272: 21726-34.
58
Furman MI,
Benoit SE,
Barnard MR.
et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31: 352-8.
60
Michelson AD,
Furman MI,
Goldschmidt-Clermont P.
et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013-8.